Tolero Pharmaceuticals Advances Investigational Agent TP-0903 into Phase 1b Expansion Stage of Study in Patients with Advanced Solid Tumors
SUMITOMO CHEM UNSP/ADR (SOMMY)
NASDAQ:AMEX Investor Relations:
sumitomo-chem.co.jp/english/ir
Company Research
Source: PR Newswire
SALT LAKE CITY, May 30, 2019 /PRNewswire/ -- Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today announced the initiation of the Phase 1b expansion stage of its ongoing Phase 1 study evaluating the investigational agent TP-0903, an AXL receptor tyrosine kinase (RTK) inhibitor, in patients with advanced solid tumors. The maximum tolerated dose (MTD) of TP-0903 was established during the Phase 1a portion of the study, allowing the study to advance to the Phase 1b stage. AXL inhibition by TP-0903 has shown to have anti-tumor activity and to reverse mesenchymal phenotype, leading to immune surveillance inhibition in preclinical models resistant to targeted agents including immunotherapeutics.1 The Phase 1b stage of the study will enroll additional patients with specific solid tumor types, including advanced solid tumors with progressive disease post immunotherapy, EGFR positive non-small cell lu
Show less
Read more
Impact Snapshot
Event Time:
SOMMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SOMMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SOMMY alerts
High impacting SUMITOMO CHEM UNSP/ADR news events
Weekly update
A roundup of the hottest topics
SOMMY
News
- China Veterinary Medicine Market Analysis Report 2024-2030, Featuring China Animal Husbandry Industry, Boehringer Ingelheim, Bimeda, Merck, CEVA, Zoetis Services, Virbac and Vetoquinol [Yahoo! Finance]Yahoo! Finance
- Roivant announces $1.5B share buyback, positive Phase 2 data Apr. 02, 2024 9:20 AM ET By: Val Brickates Kennedy , SA News Editor [Seeking Alpha]Seeking Alpha
- Poxel to Report Its 2023 Annual Results by the End of April 2024 [Yahoo! Finance]Yahoo! Finance
- Sumitomo Chemical and Valent BioSciences Announce Divestiture of Pace International and Future Collaboration with AgroFresh Solutions in the Postharvest Solutions Space [Yahoo! Finance]Yahoo! Finance
- Sumitomo Chemical and Valent BioSciences Announce Divestiture of Pace International and Future Collaboration with AgroFresh Solutions in the Postharvest Solutions SpaceBusiness Wire